97 related articles for article (PubMed ID: 21264862)
41. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
Alavian SM; Tabatabaei SV; Keshvari M; Behnava B; Miri SM; Elizee PK; Lankarani KB
Liver Int; 2010 Sep; 30(8):1173-80. PubMed ID: 20629950
[TBL] [Abstract][Full Text] [Related]
42. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
43. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
Lee SS; Kilvert L; Liu H; Trepanier J
Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
[No Abstract] [Full Text] [Related]
44. Identifying HCV genotype 1 patients at risk of relapse.
Deschênes M; Bain VG; Lee SS; Sherman M; Cooper CL; Yoshida EM; Marotta PJ; Krajden M; Usaty C; Balshaw R; Peltekian KM;
Eur J Gastroenterol Hepatol; 2010 May; 22(5):546-51. PubMed ID: 20216320
[TBL] [Abstract][Full Text] [Related]
45. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.
Yoneda S; Umemura T; Katsuyama Y; Kamijo A; Joshita S; Komatsu M; Ichijo T; Matsumoto A; Yoshizawa K; Ota M; Tanaka E;
J Infect Dis; 2011 Apr; 203(8):1087-95. PubMed ID: 21398397
[TBL] [Abstract][Full Text] [Related]
46. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Intervirology; 2012; 55(3):231-41. PubMed ID: 21734353
[TBL] [Abstract][Full Text] [Related]
47. Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.
Espírito-Santo MP; Brandão-Mello CE; Marques VA; Lampe E; Almeida AJ
Ann Hepatol; 2013; 12(3):373-9. PubMed ID: 23619253
[TBL] [Abstract][Full Text] [Related]
48. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
[No Abstract] [Full Text] [Related]
49. Hepatitis C virus: How genetic variability affects pathobiology of disease.
Chayama K; Hayes CN
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():83-95. PubMed ID: 21199518
[TBL] [Abstract][Full Text] [Related]
50. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Hepatology; 2012 Dec; 56(6):2134-41. PubMed ID: 22806754
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
[TBL] [Abstract][Full Text] [Related]
52. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Berg T; Andreone P; Pol S; Roberts S; Younossi Z; Diago M; Lawitz EJ; Focaccia R; Foster GR; Horban A; Lonjon-Domanec I; DeMasi R; Picchio G; Luo D; De Meyer S; Zeuzem S
Liver Int; 2015 Feb; 35(2):448-54. PubMed ID: 25319731
[TBL] [Abstract][Full Text] [Related]
53. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
Donlin MJ; Cannon NA; Aurora R; Li J; Wahed AS; Di Bisceglie AM; Tavis JE;
PLoS One; 2010 Feb; 5(2):e9032. PubMed ID: 20140258
[TBL] [Abstract][Full Text] [Related]
54. Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.
Tadokoro K; Kobayashi M; Suzuki F; Tanaka C; Yamaguchi T; Nagano M; Egashira T; Kumada H
J Virol Methods; 2013 Apr; 189(1):221-7. PubMed ID: 23124003
[TBL] [Abstract][Full Text] [Related]
55. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy.
Gallegos-Orozco JF; Rakela J; Rosati MJ; Vargas HE; Balan V
Dig Dis Sci; 2008 Sep; 53(9):2564-8. PubMed ID: 18594984
[TBL] [Abstract][Full Text] [Related]
56. Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
Silva C; Ianna E; Jones T; Davis JS
Hepatology; 2015 Aug; 62(2):660-1. PubMed ID: 25380552
[No Abstract] [Full Text] [Related]
57. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
Loulergue P; Mir O; Sogni P
AIDS; 2012 Mar; 26(5):655-6. PubMed ID: 22398573
[No Abstract] [Full Text] [Related]
58. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Loustaud-Ratti V; Carrier P; Rousseau A; Maynard M; Babany G; Alain S; Trépo C; De Ledinghen V; Bourlière M; Pol S; Di Martino V; Zarski JP; Pinta A; Sautereau D; Marquet P;
Dig Liver Dis; 2011 Nov; 43(11):850-5. PubMed ID: 21596633
[TBL] [Abstract][Full Text] [Related]
59. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.
Maynard M; Pradat P; Berthillon P; Picchio G; Voirin N; Martinot M; Marcellin P; Trepo C
J Viral Hepat; 2003 Jul; 10(4):318-23. PubMed ID: 12823600
[TBL] [Abstract][Full Text] [Related]
60. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.
Ogata F; Akuta N; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 Jun; 90(6):1087-1093. PubMed ID: 29427443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
